Date: 2015-05-19
Type of information: Distribution agreement
Compound: Influenza HA Vaccine KAKETSUKEN
Company: Takeda Pharmaceutical (Japan) The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) (Japan)
Therapeutic area: Infectious diseases
Type agreement: distribution
Action mechanism: vaccine
Disease: seasonal influenza
Details: * On May 19, 2015, Takeda Pharmaceutical announced that it has entered into an agreement with the Chemo-Sero-Therapeutic Research Institute for distribution of Kaketsuken’s seasonal influenza vaccine (Influenza HA Vaccine “KAKETSUKEN,”) in Japan, beginning in the upcoming season, 2015-2016. Takeda will continue to distribute the seasonal influenza vaccine, Influenza HA Vaccine “SEIKEN,” manufactured by Denka Seiken. In 2014, Takeda received approval for the new drug application of Cell Culture-based Influenza vaccine for prevention of pandemic influenza, and is currently developing a cell culture-based seasonal influenza vaccine (Development code: TAK-850).
Financial terms:
Latest news:
